Early safety check: new drug combo tested in kidney and liver patients

NCT ID NCT06911320

Completed Knowledge-focused Sponsor: Atea Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-stage study is testing a single dose of the drug combination bemnifosbuvir/ruzasvir in 28 adults. Some participants have severe kidney or liver impairment, while others are healthy. The goal is to see how the body processes the drug and whether it is safe in these groups. No treatment benefit is expected from this study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bemnifosbuvir and ruzasvir (fixed-dose combination)
What this could lead to: If successful, this study could help determine safe dosing of this drug combination for people with severe kidney or liver impairment.
What could go wrong: This is a very early Phase 1 trial with only 28 participants. It is designed to measure drug levels and safety, not to treat any disease. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER STUDY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease kidney failure liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER STUDY HEPATIC IMPAIRMENT RENAL IMPAIRMENT

Contacts and locations

Locations

Atea Study Site

Orlando, Florida, 32809, United States
Atea Study Site

Tampa, Florida, 33603, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.